Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy ...

Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...

GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with ...

AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to harvest, modify ...

Leads the development of in vivo cell therapies at Umoja Biopharma, working to unlock the full potential of CAR T cells for cancer and other serious diseases. The company’s state-of-the-art ...

Leaders from BioMed Realty, Fitzsimons Innovation Community, J.P. Morgan, and Umoja Biopharma Join CBSA Board Colorado BioScience Association (CBSA), which creates co-opportunity for Colorado’s ...